Top
Main
 
All Outcomes
 
Feedback
Home
c19early.org COVID-19 treatment researchAcetaminophenAcetaminophen (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

Loading...
More

Supplementary Data — Acetaminophen for COVID-19: real-time meta analysis of 27 studies

@CovidAnalysis, July 2024, Version 22V22
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rinott -473% 5.73 [0.30-109] death 3/85 0/49 OT​1 Improvement, RR [CI] Treatment Control Rinott -534% 6.34 [0.84-47.6] oxygen 11/85 1/49 OT​1 Lapi (ES) -15% 1.15 [0.92-1.43] death/hosp. n/a n/a Lapi (ES) -29% 1.29 [0.61-2.73] death/hosp. n/a n/a Sharif -77% 1.77 [0.39-8.09] death 9/361 2/142 Chen -32% 1.32 [0.98-1.78] PASC 98/232 39/122 LONG COVID Chen -1% 1.01 [0.67-1.52] PASC 16/41 121/313 LONG COVID Rahman -23% 1.23 [0.96-1.56] hosp. 84/244 100/356 Ravichandran (PSM) -2700% 28.00 [3.91-200] oxygen 28/72 1/72 OT​1 Ravichandran -75% 1.75 [1.48-2.06] recov. time 72 (n) 72 (n) OT​1 Ravichandran -117% 2.17 [1.72-2.72] recov. time 72 (n) 72 (n) OT​1 Ravichandran -167% 2.67 [2.00-3.56] recov. time 72 (n) 72 (n) OT​1 Manjani -220% 3.20 [1.51-6.82] death 64/388 7/136 Manjani -434% 5.34 [1.98-14.4] ventilation 388 (n) 136 (n) Manjani -244% 3.44 [1.49-8.54] progression 132 (n) 136 (n) Manjani -201% 3.01 [1.40-7.07] progression 256 (n) 136 (n) Manjani -100% 2.00 [1.33-3.02] hosp. time 388 (n) 136 (n) Lerner -27% 1.27 [0.96-1.68] death 5,783 (all patients) Ravichandran (RCT) -43% 1.43 [1.14-1.78] no recov. 77/107 52/103 OT​1 Ravichandran (RCT) -3925% 40.25 [2.47-657] progression 20/107 0/103 OT​1 Ravichandran (RCT) -133% 2.33 [1.82-3.00] recov. time 107 (n) 103 (n) OT​1 Ravichandran (RCT) -75% 1.75 [1.48-2.06] recov. time 107 (n) 103 (n) OT​1 Ravichandran (RCT) -75% 1.75 [1.48-2.06] recov. time 107 (n) 103 (n) OT​1 Ravichandran (RCT) -20% 1.20 [0.93-1.56] viral+ 43/60 37/62 OT​1 Lapi -75% 1.75 [1.40-2.18] death/hosp. n/a n/a Abolhassani -56% 1.56 [0.58-4.18] death 3/6 8/25 Baldia (ICU) 12% 0.88 [0.72-1.07] death 1,166 (n) 1,480 (n) ICU patients Baldia (ICU) 14% 0.86 [0.72-1.03] death 1,166 (n) 1,480 (n) ICU patients Stufano -19% 1.19 [0.70-2.02] PASC 11/23 23/57 Sobhy (DB RCT) -110% 2.10 [1.05-4.20] ICU 21/90 10/90 OT​1 Sobhy (DB RCT) -110% 2.10 [1.05-4.20] oxygen 21/90 10/90 OT​1 Sobhy (DB RCT) -36% 1.36 [1.07-1.73] hosp. time 90 (n) 90 (n) OT​1 Sobhy (DB RCT) -33% 1.33 [0.31-5.79] no recov. 4/90 3/90 OT​1 Sobhy (DB RCT) -75% 1.75 [0.77-3.97] no recov. 14/90 8/90 OT​1 Sobhy (DB RCT) -92% 1.92 [1.05-3.52] no recov. 25/90 13/90 OT​1 Sobhy (DB RCT) -70% 1.70 [1.06-2.72] no recov. 34/90 20/90 OT​1 Blanc -51% 1.51 [0.82-2.84] cases 60 (n) 119 (n) Kolin -23% 1.23 [1.05-1.43] cases 397,064 (all patients) Park (PSM) 25% 0.75 [0.35-1.59] death 12/397 16/397 OT​1 Park (PSM) 38% 0.62 [0.19-1.89] ventilation 5/397 8/397 OT​1 Gálvez-Barrón -47% 1.47 [0.66-3.33] death 43 (n) 60 (n) Gálvez-Barrón 23% 0.77 [0.35-1.71] severe case 43 (n) 60 (n) Reese (PSM) -61% 1.61 [1.40-1.84] death 20,826 (n) 20,826 (n) Reese (PSM) -816% 9.16 [8.72-9.63] severe case 20,826 (n) 20,826 (n) Chandan (PSM) -18% 1.18 [0.83-1.64] death 71/8,595 79/8,595 OT​1 CT​2 Chandan (PSM) -27% 1.27 [0.90-1.75] cases 8,595 (n) 8,595 (n) OT​1 CT​2 Oh 2% 0.98 [0.38-2.49] death 58 (n) 7,655 (n) Leal 7% 0.93 [0.91-0.96] cases n/a n/a Moreno-Martos -29% 1.29 [1.27-1.32] hosp. Moreno-Martos -52% 1.52 [1.28-1.79] hosp. 103/178 196/514 Moreno-Martos -5% 1.05 [0.91-1.22] hosp. 87/144 360/626 Moreno-Martos 22% 0.78 [0.63-0.98] hosp. 64/319 1,585/6,181 Moreno-Martos -16% 1.16 [1.13-1.20] hosp. Moreno-Martos -57% 1.57 [1.50-1.65] hosp. 1,090/1,868 3,414/9,188 Moreno-Martos -47% 1.47 [1.40-1.54] hosp. 1,397/2,875 3,214/9,735 MacFadden -48% 1.48 [1.44-1.51] cases n/a n/a Campbell (PSW) -1% 1.01 [0.99-1.02] death 2,074 (n) 20,311 (n) Campbell (PSW) 0% 1.00 [0.99-1.02] death 2,074 (n) 20,311 (n) Xie -5% 1.05 [0.70-1.56] hosp. population-based cohort OT​1 Xie 3% 0.97 [0.72-1.29] cases population-based cohort OT​1 Kim (PSM) -71% 1.71 [0.69-4.24] death 12/162 7/162 OT​1 Kim (PSM) -14% 1.14 [0.42-3.08] ventilation 8/162 7/162 OT​1 Kim (PSM) 40% 0.60 [0.15-2.47] ICU 3/162 5/162 OT​1 Kim (PSM) -9% 1.09 [0.64-1.86] oxygen 24/162 22/162 OT​1 Ritsinger -21% 1.21 [1.17-1.25] death 24,641 (n) 20,225 (n) Acetaminophen COVID-19 outcomes c19early.org July 2024 1 OT: comparison with other treatment2 CT: study uses combined treatment Favors acetaminophen Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit